Search

Your search keyword '"Ameye, L."' showing total 622 results
Start Over Author "Ameye, L."
622 results on '"Ameye, L."'

2. Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer

Author

Condorelli, M., Bruzzone, M., Ceppi, M., Ferrari, A., Grinshpun, A., Hamy, A.S., de Azambuja, E., Carrasco, E., Peccatori, F.A., Di Meglio, A., Paluch-Shimon, S., Poorvu, P.D., Venturelli, M., Rousset-Jablonski, C., Senechal, C., Livraghi, L., Ponzone, R., De Marchis, L., Pogoda, K., Sonnenblick, A., Villarreal-Garza, C., Córdoba, O., Teixeira, L., Clatot, F., Punie, K., Graffeo, R., Dieci, M.V., Pérez-Fidalgo, J.A., Duhoux, F.P., Puglisi, F., Ferreira, A.R., Blondeaux, E., Peretz-Yablonski, T., Caron, O., Saule, C., Ameye, L., Balmaña, J., Partridge, A.H., Azim, H.A., Demeestere, I., and Lambertini, M.

Published
2021
Full Text
View/download PDF

9. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Author

Gebhart, G., Lamberts, L.E., Wimana, Z., Garcia, C., Emonts, P., Ameye, L., Stroobants, S., Huizing, M., Aftimos, P., Tol, J., Oyen, W.J.G., Vugts, D.J., Hoekstra, O.S., Schröder, C.P., Menke-van der Houven van Oordt, C.W., Guiot, T., Brouwers, A.H., Awada, A., de Vries, E.G.E., and Flamen, P.

Published
2016
Full Text
View/download PDF

12. 69P Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial

Author

Maurer, C., primary, Agostinetto, E., additional, Ameye, L., additional, Lambertini, M., additional, Martel, S., additional, Ponde, N.F., additional, Brandão, M., additional, Poggio, F., additional, Ferreira, A.R., additional, Schiff, R., additional, De Angelis, C., additional, Gelber, R.D., additional, Dent, S., additional, Thomssen, C., additional, Piccart, M., additional, and de Azambuja, E., additional

Published
2022
Full Text
View/download PDF

13. 98P Neo-CheckRay, radiation therapy and adenosine pathway blockade to potentiate benefit of immuno-chemotherapy in early stage luminal B breast cancer: Results of the safety run-in phase

Author

De Caluwe, A., primary, Romano, E., additional, Poortmans, P., additional, Gombos, A., additional, Laragione, A., additional, Agostinetto, E., additional, Nader Marta, G., additional, Picchia, S., additional, Vandekerkhove, C., additional, Ameye, L., additional, Craciun, L., additional, Veys, I., additional, Van Gestel, D., additional, Larsimont, D., additional, Sotiriou, C., additional, Piccart, M., additional, Ignatiadis, M., additional, and Buisseret, L., additional

Published
2022
Full Text
View/download PDF

17. Impact of female obesity and assisted reproduction on uncomplicated pregnancies and healthy births: a study of 428 336 births in Flanders.

Author

Wuytack, F, Devlieger, R, Ameye, L, Corcoran, P, Fitzgerald, A P, Ombelet, W, and Bogaerts, A

Subjects
REPRODUCTIVE technology, HIGH-risk pregnancy, OBESITY in women, WEIGHT gain, PREGNANCY complications, FERTILIZATION in vitro
Abstract

STUDY QUESTION What is the impact of BMI on uncomplicated pregnancies and healthy births in women who did or did not have medically assisted reproduction (MAR, i.e. ART or hormonal stimulation without manipulation of eggs or embryos) in the Flanders region (Belgium)? SUMMARY ANSWER Women with a higher BMI who use MAR are at the highest risk of pregnancy and birth complications. WHAT WE KNOW ALREADY Medically assisted reproduction (MAR) is used increasingly worldwide and is associated with increased risk of adverse perinatal outcomes. Obesity is also increasing globally and obese women are more likely to seek MAR since obesity is associated with infertility. When obese women undergo MAR, the risk of adverse outcomes may be enhanced but it is not clear to what extent. STUDY DESIGN, SIZE, DURATION We conducted a registry-based study using the data from the Study Centre for Perinatal epidemiology database for years 2009–2015, region of Flanders, Belgium. This included 428 336 women. PARTICIPANTS/MATERIALS, SETTING, METHODS The average age was 30.0 years (SD 4.78), 194 061 (45.31%) were nulliparous, and 6.3% (n = 26 971) conceived with MAR. We examined the association of BMI and MAR with the following composite primary outcomes: 'uncomplicated pregnancy and birth' and 'healthy baby'. We conducted Poisson regression and adjusted for maternal age, parity, gestational weight gain, smoking and previous caesarean section. MAIN RESULTS AND THE ROLE OF CHANCE In our study, 36.80% (n = 157 623) of women had an uncomplicated pregnancy and birth according to the definition used. The predicted probability of having an uncomplicated pregnancy and birth for women with a BMI of 25 kg/m2 who conceived spontaneously was 0.33 (0.32 to 0.35), while it was 0.28 (0.24 to 0.32) for women who used hormonal stimulation and 0.26 (0.22 to 0.29) for women who used IVF/ICSI. This probability reduced with increasing BMI category for both MAR and non-MAR users. For women with a BMI of 30 kg/m2, the predicted probability of having an uncomplicated pregnancy and birth was 0.28 (0.26 to 0.30) for women who conceived spontaneously, and 0.22 (0.16 to 0.29) and 0.20 (0.14 to 0.26) for women who used hormonal stimulation only or IVF/ICSI, respectively. The predicted probability of having a healthy baby for women with a BMI of 25 kg/m2 who conceived spontaneously was 0.92 (0.91 to 0.93), 0.89 (0.87 to 0.92) for women who used hormonal stimulation only and 0.85 (0.84 to 0.87) for women who used IVF/ICSI. LIMITATIONS, REASONS FOR CAUTION The database did not include data on socio-economic status, pre-pregnancy morbidities and paternal BMI. Subsequently, we could not adjust for these factors in the analysis. WIDER IMPLICATIONS OF THE FINDINGS Obese women who use MAR are at the highest risk of pregnancy and birth complications. This increase in interventions also has cost and resource implications which is relevant for funding policies. Weight loss interventions prior to MAR seem plausible but their (cost-) effectiveness needs urgent investigation. STUDY FUNDING/COMPETING INTEREST(S) F.W. received an Erasmus Plus training grant to visit A.B. L.A. and R.D. and conducted this study during this visit. The authors have no competing interest to declare. TRIAL REGISTRATION NUMBER N/A. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Vessel morphology depicted by three-dimensional power Doppler ultrasound as a second stage test in difficult adnexal tumors: a prospective diagnostic accuracy study

Author

Sladkevicius, P, Jokubkiene, L, Timmerman, D, Fischerova, D, Van Holsbeke, C, Franchi, D, Savelli, L, Epstein, E, Fruscio, R, Kaijser, J, Czekierdowski, A, Guerriero, S, Angela Pascual, M, Testa, A, Ameye, L, Valentin, L, Sladkevicius, P, Jokubkiene, L, Timmerman, D, Fischerova, D, Van Holsbeke, C, Franchi, D, Savelli, L, Epstein, E, Fruscio, R, Kaijser, J, Czekierdowski, A, Guerriero, S, Angela Pascual, M, Testa, A, Ameye, L, and Valentin, L

Subjects
Doppler, ultrasonography, ovarian neoplasm, three-dimensional ultrasound, vascular morphology
Abstract

Objectives: To assess whether vessel morphology depicted by three-dimensional (3D) power Doppler ultrasound improves discrimination between benignity and malignancy if used as a second-stage test in adnexal masses that are difficult to classify. Methods: This was a prospective observational international multicenter diagnostic accuracy study. Consecutive patients with an adnexal mass underwent standardized transvaginal two-dimensional (2D) grayscale and color or power Doppler and 3D power Doppler ultrasound examination by an experienced examiner, and those with a ‘difficult’ tumor were included in the current analysis. A difficult tumor was defined as one in which the International Ovarian Tumor Analysis (IOTA) logistic regression model-1 (LR-1) yielded an ambiguous result (risk of malignancy, 8.3% to 25.5%), or as one in which the ultrasound examiner was uncertain regarding classification as benign or malignant when using subjective assessment. Even when the ultrasound examiner was uncertain, he/she was obliged to classify the tumor as most probably benign or most probably malignant. For each difficult tumor, one researcher created a 360° rotating 3D power Doppler image of the vessel tree in the whole tumor and another of the vessel tree in a 5-cm3 spherical volume selected from the most vascularized part of the tumor. Two other researchers, blinded to the patient's history, 2D ultrasound findings and histological diagnosis, independently described the vessel tree using predetermined vessel features. Their agreed classification was used. The reference standard was the histological diagnosis of the mass. The sensitivity of each test for discriminating between benign and malignant difficult tumors was plotted against 1 – specificity on a receiver-operating-characteristics diagram, and the test with the point furthest from the reference line was considered to have the best diagnostic ability. Results: Of 2403 women with an adnexal mass, 376 (16%) had a difficult mass. Ultrasound volumes were available for 138 of these cases. In 79/138 masses, the ultrasound examiner was uncertain about the diagnosis based on subjective assessment, in 87/138, IOTA LR-1 yielded an ambiguous result and, in 28/138, both methods gave an uncertain result. Of the masses, 38/138 (28%) were malignant. Among tumors that were difficult to classify as benign or malignant by subjective assessment, the vessel feature ‘densely packed vessels’ had the best discriminative ability (sensitivity 67% (18/27), specificity 83% (43/52)) and was slightly superior to subjective assessment (sensitivity 74% (20/27), specificity 60% (31/52)). In tumors in which IOTA LR-1 yielded an ambiguous result, subjective assessment (sensitivity 82% (14/17), specificity 79% (55/70)) was superior to the best vascular feature, i.e. changes in the diameter of vessels in the whole tumor volume (sensitivity 71% (12/17), specificity 69% (48/70)). Conclusion: Vessel morphology depicted by 3D power Doppler ultrasound may slightly improve discrimination between benign and malignant adnexal tumors that are difficult to classify by subjective ultrasound assessment. For tumors in which the IOTA LR-1 model yields an ambiguous result, subjective assessment is superior to vessel morphology as a second-stage test.

Published
2021

23. 72TiP ROSALINE: A phase II, single-arm, neoadjuvant study of targeting ROS1 in combination with endocrine therapy (ET) in invAsive Lobular carcINoma of the brEast

Author

Agostinetto, E., primary, Paesmans, M., additional, Ameye, L., additional, Veys, I., additional, Buisseret, L., additional, Neven, P., additional, Taylor, D., additional, Fontaine, C., additional, Duhoux, F.P., additional, Canon, J-L., additional, Denys, H., additional, Coussy, F., additional, Chakiba, C., additional, Pistilli, B., additional, Piccart, M., additional, Ignatiadis, M., additional, and Aftimos, P.G., additional

Published
2021
Full Text
View/download PDF

27. Vessel morphology depicted by three‐dimensional power Doppler ultrasound as second‐stage test in adnexal tumors that are difficult to classify: prospective diagnostic accuracy study

Author

Sladkevicius, P., primary, Jokubkiene, L., additional, Timmerman, D., additional, Fischerova, D., additional, Van Holsbeke, C., additional, Franchi, D., additional, Savelli, L., additional, Epstein, E., additional, Fruscio, R., additional, Kaijser, J., additional, Czekierdowski, A., additional, Guerriero, S., additional, Pascual, M. A., additional, Testa, A. C., additional, Ameye, L., additional, and Valentin, L., additional

Published
2021
Full Text
View/download PDF

34. Corrigendum to “Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials”

Author

Franzoi, M.A., primary, Ameye, L., additional, Eiger, D., additional, Piccart, M., additional, Brandão, M.D.R.A., additional, Pondé, N., additional, Desmedt, C., additional, Di Cosimo, S., additional, Paesmans, M., additional, Caparica, R., additional, Kotecki, N., additional, Lambertini, M., additional, De Angelis, C., additional, Awada, A.H., additional, and de Azambuja, E., additional

Published
2020
Full Text
View/download PDF

46. 153P Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials

Author

Franzoi, M.A., primary, Ameye, L., additional, Eiger, D., additional, Piccart, M., additional, Brandão, M.D.R.A., additional, Pondé, N., additional, Desmedt, C., additional, Di Cosimo, S., additional, Paesmans, M., additional, Caparica, R., additional, Kotecki, N., additional, Lambertini, M., additional, De Angelis, C., additional, Awada, A.H., additional, and de Azambuja, E., additional

Published
2020
Full Text
View/download PDF

49. SUN-PO116: Fat Quality Correlates with Prognosis of Esophageal Cancer

Author

Anciaux, M., primary, Van Gossum, A., additional, Wenglinski, C., additional, Ameye, L., additional, Guiot, T., additional, Flamen, P., additional, Demetter, P., additional, Deleporte, A., additional, Paesmans, M., additional, Donckier, V., additional, Hendlisz, A., additional, and Vandeputte, C., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results